Novo Nordisk has secured approval for Victoza (liraglutide) from the US Food and Drug Administration (FDA) to treat paediatric patients aged ten years or older with type 2 diabetes.

Victoza is claimed to be the first non-insulin drug approved to treat the condition in paediatric patients. It has been used for adult patients since 2010.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Acting director at the FDA Center for Drug Evaluation and Research’s Division of Metabolism and Endocrinology Products (DMEP) Lisa Yanoff said: “Victoza has now been shown to improve blood sugar control in paediatric patients with type 2 diabetes.

“The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”

When administered, Victoza works by creating the same effects in the body as the glucagon-like peptide (GLP-1) receptor protein in the pancreas and improves blood sugar levels.

Victoza slows digestion, prevents the liver from making too much glucose, and helps the pancreas produce more insulin when needed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can also be used to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.

Novo Nordisk carried out several placebo-controlled trials in adults and one placebo-controlled trial with 134 pediatric patients to evaluate the efficacy and safety of Victoza for reducing blood sugar in patients with type 2 diabetes.

The drug is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. No clinical trials were conducted to study the effect of the drug on major adverse CV events in paediatrics.